A new beadlet technology with a patent pending has been developed to deliver stable and bioavailable Nicotinamide Mononucleotide (NMN). This technology aims to boost NAD+ levels, support cellular regeneration, and help individuals feel younger by leveraging the benefits of NMN. The innovation was announced in Los Angeles on June 18, 2026, by the renowned health and wellness brand Gundry MD®. Their initiative focuses on enhancing overall well-being through this groundbreaking approach.